CTI's Pixuvri wins French reimbursement despite "weak" medical benefit
This article was originally published in Scrip
Executive Summary
Cell Therapeutics' Pixuvri (pixantrone) has scraped through the French health technology appraisal process, offering "weak" medical benefit, and "no therapeutic progress", according to French HTA authorities. Nevertheless, CTI remains upbeat and is working to get the drug on the reimbursement list for hospitals.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.